Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critically appraised research paper.

Abstract

Dystrophic epidermolysis bullosa (DEB) is a rare inherited blistering skin disease that causes lifelong, slow-to-heal wounds, which predispose patients to chronic inflammation, scarring and an increased risk of developing squamous cell carcinoma. Management is largely supportive with no approved corrective therapies currently available. We critically appraise the phase III clinical trial reported by Guide et al., investigating the topical application of beremagene geperpavec on cutaneous wounds in DEB.